Origin Therapeutics, an actively managed investment issuer focused on making equity investments in psychedelics-related companies, has filed its prospectus with plans to go public, and has announced its first five portfolio companies:
-
Microdose Psychedelic Insights aims to unlock the potential of psychedelics through Industry events, market intelligence, original evidence-based content, strategy, and community. It intends to enable and empower society at large to make better, more mindful decisions about psychedelics and their intersection with healthcare, medicine, and personal growth.
-
Ocean Bio Ltd. is an early-stage drug discovery company that is focused on the design of novel psychedelic therapeutics that may have desirable therapeutic applications, while minimizing possible negative side effects that are otherwise associated with traditional psychedelics.
-
Dimensions Health Centres Inc. integrates the latest developments in neuroscience and neurobiology to create a novel approach to mental health and well-being. Dimensions will provide immersive, psychedelic (once legally permitted), and psychedelic-inspired nature retreats for education and transformational healing.
-
Xpira Pharmaceuticals Inc. is focused on the development, production, and marketing of psychedelic-based products, as legally permitted, with clinically proven efficacy. Xpira’s scientific team has undertaken the research and development of psychedelic drug Treatments and delivery systems for improved psychedelic-assisted psychotherapy, where legally permitted.
-
Tripsitter Clinic Corp. is a mobile-first, responsive web app that acts as a virtual clinic, connecting patients with an experienced medical practitioner. TripSitter operates as a “software as a service” (SaaS) platform, functioning as the intermediary between patient and practitioner attempting to replicate the successful results of the “Yale Protocol” through a Telehealth delivery platform using different mechanisms such as nasal sprays and troches.
Press release and full descriptions below. Let me know if you have any questions or if you would like to interview the CEO, Alexander Somjen, about his predictions for which areas we will see leading the psychedelics industry and why these companies were selected.
